Aflac stays a Buy despite Q1 earnings miss, backed by policy growth and strong dividends.

Aflac missed earnings expectations in Q1 but remains a Buy due to steady organic policy growth, consistent dividend increases, and a strong balance sheet. The company is expanding in Asia and niche markets like pet insurance, which could drive future growth despite uneven revenue trends. Favorable margins, low expenses, and strong credit ratings support its financial health, though valuation multiples suggest limited near-term upside. Dividend growth of 16% year-over-year and a low payout ratio make Aflac attractive for income-focused investors, with technical indicators also pointing to a bullish trend after recent recovery signals.